Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18

Oncology Reports

Volumn 16, Issue 4, 2006, Pages 713-719

  Chikkanna Gowda, C P ^a   McNally, S ^a   Sheahan, B J ^b   Fleeton, M N ^a   Atkins, G J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Ct26 tumours; Interleukin 18; K balb tumours; Semliki forest virus vector; Tumour inhibition

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 18;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; HAMSTER; METABOLISM; METHODOLOGY; MOUSE; NECROSIS; NEOPLASM; SEMLIKI FOREST ALPHAVIRUS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CRICETINAE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; INTERFERON TYPE II; INTERLEUKIN-18; MICE; MICE, INBRED BALB C; NECROSIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; SEMLIKI FOREST VIRUS;

EID: 34147108731     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.4.713     Document Type: Article

References (26)

1. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T and Nakanishi K: IL-18. In: Cytokine Reference. Vol. 1. Academic Press, San Francisco, 2001.
2. Dinarello CA and Fantuzzi G: Interleukin-18 and host defense against infection. J Infect Dis 187: 370-384, 2003.
3. Micallef MJ, Yoshida K, Kawai S, et al: In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 43: 361-367, 1997. (Pubitemid 27102222)
4. Yamanaka K, Hara I, Nagai H, et al: Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol Immunother 48: 297-302, 1999. (Pubitemid 29434189)
5. Hara I, Nagai H, Miyake H, et al: Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 7: 83-90, 2000. (Pubitemid 30080991)
6. Oshikawa K, Shi F, Rakhmilevich AL, Sondel PM, Mahvi DM and Yang NS: Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. Proc Natl Acad Sci USA 96: 13351-13356, 1999.
7. Tatsumi T, Huang J, Gooding WE, et al: Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 63: 6378-6386, 2003. (Pubitemid 37255187)
8. Coughlin CM, Salhany KE, Wysocka M, et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101: 1441-1452, 1998. (Pubitemid 28145262)
9. Han M, Zheng S, Yu J, Peng J, Guo Q and Wang J: Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity. J Zhejiang Univ Sci 5: 472-476, 2004.
10. Yamanaka R, Tsuchiya N, Yajima N, et al : Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 99: 746-753, 2003. (Pubitemid 37168045)
11. Hara S, Nagai H, Miyake H, et al : Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity. J Urol 165: 2039-2043, 2001.
12. Nakamura S, Otani, T, Ijiri Y, Motoda R, Kurimoto M and Orita K: IFN-γ-dependent and independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J Immunol164: 3330-3336, 2000. (Pubitemid 30148998)
13. Lundstrom K: Alphavirus vectors for gene therapy applications. Curr Gene Ther 1: 19-29, 2001.
14. Atkins GJ, Smyth JW, Fleeton MN, Galbraith SE and Sheahan BJ: Alphaviruses and their derived vectors as anti-tumor agents. Curr Cancer Drug Targets 4: 597-607, 2004. (Pubitemid 39536380)
15. Karlsson GB and Liljestrom P: Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors. Methods Mol Biol 246: 543-557, 2004.
16. Berglund P, Sjoberg M, Garoff H, Atkins GJ, Sheahan BJ and Liljestrom P: Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology 11: 916-920, 1993. (Pubitemid 23218980)
17. Smerdou C and Liljestrom P: Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol 73: 1092-1098, 1999. (Pubitemid 29036760)
18. Lundstrom K, Schweitzer C, Rotmann D, Hermann D, Schneider EM and Ehrengruber MU: Semliki Forest virus vectors: efficient vehicles for in vitro and in vivo gene delivery. FEBS Lett 504: 99-103, 2001. (Pubitemid 32787056)
19. Glasgow GM, McGee MM, Tarbatt CJ, Mooney DA, Sheahan BJ and Atkins GJ: The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol 79: 2405-2410, 1998. (Pubitemid 28464297)
20. Morris-Downes MM, Phenix KV, Smyth J, et al : Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19: 1978-1988, 2001. (Pubitemid 32178346)
21. Chikkanna-Gowda CP, Sheahan, BJ, Fleeton, MN and Atkins GJ: Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther 12: 1253-1263, 2005. (Pubitemid 41195116)
22. Aaronson SA and Weaver CA: Characterization of murine sarcoma virus (Kirsten) transformation of mouse and human cells. J Gen Virol 13: 245-252, 1971.
23. Stephenson JR and Aaronson SA: Antigenic properties of murine sarcoma virus-transformed BALB-3T3 nonproducer cells. J Exp Med 135: 503-515, 1972.
24. Brattain, MG, Strobel-Stevens J, Fine D, Webb M and Sarrif AM: Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 40: 2142-2146, 1980. (Pubitemid 10082214)
25. Osaki T, Hashimoto W, Gambotto A, et al: Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 6: 808-815, 1999. (Pubitemid 29243654)
26. Yoshimura K, Hazama S, Iizuka N, Yoshino S, Yamamoto K, Muraguchi M, Ohmoto Y, Noma T and Oka M: Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence. Cancer Gene Ther 8: 9-16, 2001. (Pubitemid 32151892)